Skip to main content

Table 1 Clinical characteristics at start of 3-year study

From: Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition

 Total group
Number (females)43 (25)
Genetic subtype
 Deletion / mUPD / ICD / translocation18 / 20 / 4 /1
Age at start of childhood GH treatment (yrs)7.6 (5.2 to 10.1)
Age at inclusion (yrs)
 - Males19.5 (18.7 to 20.7)
 - Females18.4 (16.9 to 20.8)
Adult height (SDS)−1.0 (− 1.7 to − 0.3)
BMI (kg/m2)24.5 (21.9 to 27.7)
BMI for age (SDS)0.9 (0.0 to 1.8)
BMI for PWS (SDS)−1.4 (−2.0 to −0.7)
Fat mass percentage (SDS)a2.2 (1.7 to 2.5)
Fat mass percentage (%)40.9 (34.4 to 45.6)
Lean body mass (SDS)a−2.3 (− 2.8 to −1.4)
GH-dose (mg/m2/day)0.33 (0.33 to 0.59)
GH-dose (mg/kg/day)0.012 (0.012 to 0.021)
IGF-I SDSa1.5 (0.6 to 2.0)
  1. Data expressed as median (IQR)
  2. mUPD Maternal uniparental disomy, ICD Imprinting center defect, GH Growth hormone
  3. aFM% SDS, LBM SDS and IGF-I SDS were calculated according to age- and sex-matched Dutch references [25]